Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA6 | P23280 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | CA7 | P43166 | 4/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.48 |
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482511 | 0.85 | CA1 (0.47) | CA1CA2CA9CA12CA4 | |
| SCHEMBL6684584 | 0.85 | CA1 (0.55) | CA1CA2CA9CA12CA4 | |
| SCHEMBL30137559 | 0.85 | CA1 (0.55) | CA1CA2CA9CA12CA4 | |
| SCHEMBL20093090 | 0.83 | ALOX5AP (0.49) | CA1CA2CA9ALOX5APFEN1 | |
| SCHEMBL1363127 | 0.83 | ALDH1A1 (0.47) | CA1CA2CA9ALOX5APFEN1 | |
| SCHEMBL1523192 | 0.82 | ALDH1A1 (0.52) | CA1CA2CA9CA12CA4 | |
| SCHEMBL29913652 | 0.81 | CA1 (0.55) | CA1CA2CA9CA12CA4 | |
| SCHEMBL2777161 | 0.81 | ALOX5AP (0.51) | CA1CA2CA9CA12CA4 | |
| SCHEMBL2182720 | 0.81 | KIF11 (0.47) | CA1CA2CA9CA12CA4 | |
| SCHEMBL30543023 | 0.81 | ALOX5AP (0.51) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| US-7268129-B2 | Fluorinated benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-09-11 | — | — | US | disclosed |
| CN-1308317-C | New fluorinated benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-04-04 | — | — | CN | disclosed |
| CN-1680343-A | New fluorinated benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-10-12 | — | — | CN | disclosed |
| US-20050165008-A1 | Fluorinated benzothiadiazine compounds | LES LABORATORIES SERVIER (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1557412-A1 | Fluorinated benzothiadiazine derivatives and their use as AMPA receptor modulators | Les Laboratoires Servier (FR) | 2005-07-27 | — | — | EP | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| EP-0906297-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997049692-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | CA1 3478/4885CA2 4004/4885CA9 4651/4885 |
| US-20050165008-A1 | Fluorinated benzothiadiazine compounds | GRM1, GRIN1, GRIK5 | CA1 1787/4885CA2 1644/4885CA9 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.